Skip to main content

Table 5 Cell cycle distribution of SMMC-7721 cells after different drug treatments

From: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

 

G1 phase (%)/ p-value (vs control)

S phase (%)/ p-value (vs control)

G2/M phase (%)/ p-value (vs control)

Control

63.83 ± 1.94

27.17 ± 2.41

9.00 ± 2.26

S

70.07 ± 0.70/p = 0.000

8.45 ± 1.03/p = 0.000

21.51 ± 1.63/p = 0.000

F

72.23 ± 0.35/p = 0.000

25.50 ± 0.80/p = 0.188

2.27 ± 1.15/p = 0.000

(S + F)

64.73 ± 0.15/p = 0.458

29.90 ± 0.10/p = 0.041

5.37 ± 0.27/p = 0.004

S + F

81.83 ± 0.35/p = 0.000

9.23 ± 0.12/p = 0.000

8.92 ± 0.44/p = 0.939

F + S

71.22 ± 2.80/p = 0.000

27.20 ± 2.30/p = 0.978

1.08 ± 0.40/p = 0.000

  1. S: sorafenib, F: 5-FU.